Cohava Gelber is an executive with over 25 years of experience in discovery and development of immune therapeutics and diagnostics for cancer, autoimmune disease, allergies, and infectious diseases. Dr. Gelber has held various executive positions in academia (Duke University) and biopharmaceutical companies. She recently launched two companies: Caerus Discovery, LLC (CDL), with support from Biowa/ Kyowa Hakko Kirin, and Serpin Pharma with a group of private investors. CDL’s mission is to discover and develop new antibody-based therapeutics. Serpin Pharma’s mission is to develop first in class, peptide therapeutics for inflammatory diseases such as diabetes and rheumatoid arthritis.
Dr. Gelber received a PhD from the Weizmann Institute, an MBA from Cornell University, and post doctorate training at Stanford University.
The author of numerous scientific manuscripts and textbook chapters, Dr. Gelber is also the inventor of 16 granted patents and 57 patent applications.